CTOs on the Move

Argos Therapeutics

www.argostherapeutics.com

 
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient`s dendritic cells to activate an immune response specific to the patient`s disease.   Argos` most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. Argos Therapeutics is headquartered in Research Triangle Park, NC. The Company has clinical stage programs in Phase 3 (metastatic renal cell carcinoma), Phase 2b ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Brighton Pharmaceuticals

Brighton Pharmaceuticals is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Community Residences

CRi is dedicated to providing personalized resources to youth & adults with mental health needs & developmental disabilities.

Pharma Logistics

Pharma Logistics is a Mundelein, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Western Allergy Services

Western Allergy Services Ltd is a Victoria, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amolyt Pharma

Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.